The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


ESMO 2018 spotlights Merck?s Keytruda, Pfizer's Ibrance, AstraZeneca?s Lynparza and more.....           FiercePharmaAsia?China?s $1.3B vaccine fine; Lantus biosim retreat; Taiho?s VC fund.....           After Philippines safety scandal, Sanofi's Dengvaxia set for European approval.....           Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout.....           NICE spurns Lilly?s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartis.....           AbbVie CFO Chase spearheaded its Abbott spinoff and Imbruvica buy?and now he's retiring.....           GlaxoSmithKline?s job whacking touches U.S. consumer plant.....           AbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement.....           Insys drove ?explosive' opioid painkiller sales by ?owning? physicians, Senate report reveals.....           Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win.....           Clovis bolsters Rubraca's PARP-leading prostate cancer bid with big-time response data.....           Amgen, Lilly migraine drugs nab Express Scripts backing, but Teva's shut out.....           FDA spanks South Korea's Hanlim Pharm with warning letter.....           Mannkind's Afrezza Facebook page gets slapped by FDA's promo police.....           Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?.....           Minnesota AG targets Sanofi, Eli Lilly and Novo Nordisk in latest insulin pricing attack.....           U.K. fights EpiPen shortage by extending injector expiry dates.....           Working through CEO swap, Pfizer plots job cuts in drive for 'simpler' structure.....           Officials deny shortage of Seqirus' Fluad in the U.K. as season nears.....           FCB Health launches next-generation big data agency to better tell pharma brand stories.....           Sanofi, Regeneron score positive Dupixent data in sinusitis as they await key FDA asthma verdict.....           EU expands look at Zhejiang Huahai as impurities show up in other 'sartans'.....           Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms.....           Azar deals woe to DTC?and a slap to Big Pharma?with vow to force prices into drug ads.....           Neopharma snatches Dr. Reddy's API business as it continues global expansion.....           Flu shot giant Sanofi teams with American Lung Association on get-vaccinated message to U.S. seniors.....           Teva's patent failure gives long-acting Copaxone generics free rein.....           Neopharma snatches Dr. Reddy's API business as it continues global expansion.....           Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help.....           UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans.....           Cold-and-flu beverage to go? GSK launches Theraflu pods for coffee makers, backed by ad campaign.....           Novartis to acquire biopharmaceutical firm Endocyte for $2.1bn.....           AbbVie, Morphic Therapeutic to advance therapeutic for fibrotic diseases.....           Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC.....           Diurnal puts hold on US development of adrenal drug Chronocort.....           HHS Secretary Azar for attorney general? He?s not interested: WSJ.....           FiercePharmaAsia?China cancer drug discounts; Celltrion?s Rituxan biosim; Otsuka-Proteus digital pill deal.....           AbbVie inks yet another Humira biosim deal?this time with Novartis?as EU launches near.....           Bristol-Myers stumbles in lung cancer quest as I-O star Opdivo flunks small cell trial.....           Johnson & Johnson one-ups Eliquis as Xarelto nabs $1.5B FDA nod in artery disease.....           Merck ditches biosimilar Lantus, but will that ease the path for Mylan?s rival insulin product?.....           Shire opens $1B plant to make rare disease drugs.....           HHS Secretary Azar for attorney general? He?s not interested: WSJ.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
 
 
Latest news

Professional recognition for Pharmaceutical Science Degrees

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that the pharmaceutical science course at the University of Greenwich has become the first APS accredited course having successfully completed the accreditation process set up by the Academy towards the end of 2017.

This is the first time that a pharmaceutical science course has been accredited in the United Kingdom and it is also, we believe, a world first.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the UK.

The Academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

 
 
APS events overview

The APS is developing an exciting and informative programme of events in 2019.

Please take a look at our programme here.

OTHER EVENTS IN DEVELOPMENT
Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop 

Follow us
 
Upcoming Events
8th Annual MIBio Conference
15 November 2018
APS Additive Manufacturing Symposium
27 March 2019
APS Developability Workshop
17 - 18 April 2019
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.